CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of$ 1.33. This compares to loss of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 24.06%. A quarter ago, it was expected that this company would post a loss of$ 1.37 per share when it actually produced a loss of $1.49, delivering a surprise of -8.76%.Over the last four quarters, the company has s ...